Alzheimer’s Disease

Research priorities to achieve widespread use of blood-based biomarkers in Alzheimer’s disease

Blood p-tau in symptomatic and non-symptomatic AD patients

What contributes to hyperexcitability in Alzheimer’s disease?

Association between synaptic biomarkers of AD and brain function and structure

Importance of standardizing biomarker protocols in the diagnosis of AD

Boosting ketone levels for brain function: human studies

Neuronal network hyperexcitability as a biomarker in Alzheimer’s disease

The five domains of mild behavioral impairment

Buntanetap mechanism of action

Buntanetap shows promise for the treatment of Alzheimer’s disease and Parkinson’s disease

MBI associated with decreased connectivity in networks linked with Alzheimer’s disease

What drives network hyperexcitability in Alzheimer’s disease?

Anti-HMGB1 agents for the treatment of Alzheimer’s disease

New diagnostic criteria for apathy in neurocognitive disorders

What is the relationship between COVID-19 and Alzheimer’s disease?

What is the future of modifiable dementia risk factors research?